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Mutation screening of the BRCA1 and BRCA2 genes in probands with familial breast/ovarian cancer has been
greatly improved by the multiplex ligation-dependent probe amplification (MLPA) assay able to evidence gene
rearrangements not detectable by standard screening methods. However, no criteria for selection of cases to
be submitted to the MLPA test have been reported yet. We used the BRCAPro software for the selection of
familial breast/ovarian cancer probands investigated with the MLPA approach after negative BRCA1/2
conventional mutation screening. One hundred and seventy-seven probands were investigated for germline
BRCA1/2 mutations after assessment of genetic risk using BRCAPro. Probands were classified as BRCAPro
positive (n = 67) when the carrier probability (CP) was >10% and as BRCAPro negative (n = 110), when the CP
was <10%. Conventional mutational analyses of the BRCA1/2 genes and, in one case, of p53 identified 22
pathogenetic germline mutations, 12 in BRCA1, 9 in BRCA2 and 1 in p53, in 22/177 (12.4%) probands. All the
mutations except one were detected in BRCAPro-positive patients. In the 46 BRCAPro-positive cases that
resulted negative by BRCA1/2 mutation, screening analysis of rearrangements within BRCA1/2 by MLPA was
carried out. Three patients with a very high CP showed BRCA1 deletions, consisting of deletions of exons 1–2 in
two probands and of exon 24 in the third proband. In one case, the exons 1–2 deletion was shown to
cosegregate with disease in the family. No BRCA2 rearrangements were detected, but one patient showed the
1100delC of the CHEK2 gene, whose probe is present in the BRCA2 kit. In our series, the highest carrier
detection rate of mutation screening plus MLPA analysis (52.3%) was in patients with a BRCAPro CP >50%.
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introduction
Breast cancer (BC) and ovarian cancer (OC) are among the
most frequent malignancies in women, and 5%–10% of all BC/
OC cases are attributed to hereditary predisposition [1]. Point
mutations in the BRCA1 and BRCA2 genes account for a large
portion of the putative hereditary BC/OC cases, with variable
prevalences among different populations [2, 3]. It has been
indicated that genomic BRCA1/2 rearrangements, not
detectable by the techniques commonly used for the screening
of point mutations, could account for at least a portion of the
BRCA1/2 mutation-negative cases [4]. The search for genomic
rearrangements within the BRCA1/2 genes has been
considerably improved by the introduction of multiplex
ligation-dependent probe amplification (MLPA), an assay able
to detect deletions–duplications within specific genes in
a simple, fast and efficient way [5]. Using MLPA, an early study
reported a BRCA1 deletions/duplications detection rate of
>20% in northern Italian BRCA1/2 mutation-negative BC/OC
families. This indicated that screening by MLPA should be
routinely included in BRCA1 mutational analysis [6].
However, subsequent studies carried out in patient series from
different populations reported lower detection rates [7–13].
Differences in genetic background and case selection criteria
could account for discrepancies in BRCA1 deletions/
duplications detection rates between studies.
The identification of specific criteria for the selection of cases
to be submitted to MLPA analysis is therefore important.
BRCAPro, a statistical software using Mendelian genetics and
Bayesian updating, calculates the carrier probability (CP) of
BRCA1/2 mutations on the basis of the individual and familial
cancer history [14, 15]. In a previous study, we demonstrated
the usefulness of this software in the selection of cases for
BRCA1/2 mutation screening [16]. In the present study, we
report on the use of BRCAPro in the selection of probands with
personal and/or familial BC/OC history to be analyzed by
MLPA for the BRCA1/2 genes.
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patients and methods
patients
A total of 177 probands with personal and/or family history of BC and/or
OC were enrolled at two centers in Italy, Pescara Hospital, Pescara [115
probands, Central Italian Group (CIG)] and the Regional Reference Center
for the Characterization and Genetic Screening of Hereditary Tumors,
University of Palermo, Palermo [62 probands, Southern Italian Group
(SIG)]. At Pescara, 115 unrelated CIG probands who underwent genetic
counseling for BC/OC between 2000 and 2006 were selected using
previously described criteria [16]. CIG probands included 92 cancer-
affected females, of which 78 with BC (mean age at diagnosis 44.3 years; six
cases had bilateral BC, one also developed OC), 13 with OC (mean age at
diagnosis 41.4 years, one subsequently developed BC) and 1 with thyroid
cancer (a 54-year-old with BC family history). The remaining 17 female
probands were healthy first-degree relatives of BC/OC patients (not
available for mutational analysis). In addition, CIG cases comprised six
males, of which three diagnosed with BC (at ages 33, 31 and 77 years,
respectively) and three with BC family history (of which two were cancer
unaffected and one diagnosed with prostate cancer at age 51 years).
At Palermo, 62 unrelated SIG probands who underwent genetic
counseling between 1999 and 2005 were selected for this study. SIG
probands included 58 females, of which 55 affected with BC (mean age
at diagnosis: 42.9 years; eight had bilateral BC and four also OC) and
three with OC (<40 years of age). In addition, SIG cases included four
male BC patients, aged 47, 60, 62 and 62 years.
CIG and SIG probands were enrolled after approval of the study by
the local Ethical Committee. Written informed consent was always
obtained before enrollment in the study.
assessment of genetic risk using BRCAPro
For each CIG and SIG case, we calculated the CP of BRCA1/2 mutations by
means of the BRCAPro (CAGene) program. We classified probands as
BRCAPro positive or -negative when CP was >10% or <10%, respectively.
Of the total 177 probands selected for genetic analyses, 67 were BRCAPro
positive (37.8%). These included 21 probands with CP >50% (range
51.5%–100%) and 46 probands with CP <50% (range 11.2%–45.2%).
mutation screening
Genomic DNA from peripheral blood was extracted using the QIAamp
blood kit (Qiagen Inc., Chatsworth, CA) for both the CIG and SIG case
groups. Conventional mutational analysis of a subset of 68 CIG
probands was previously described [16]. For the other 47 CIG probands,
exons 1, 3–10 and 12–24 of BRCA1 and exons 2–9 and 12–27 of BRCA2
were screened by Denaturing High Performance Liquid Chromatography
(DHPLC) analysis using the WaveNucleic Acid Fragment Analysis
System (Transgenomic Inc., San Jose, CA) as previously described [17].
Samples showing altered patterns by DHPLC or truncated peptides by
Protein Truncation Test (PTT) were sequenced using an ABI Prism 310
Genetic Analyzer (Applied Biosystems, Forster City, CA). For CIG-110, in
addition to BRCA1/2 screening, exons 5–8 of the p53 gene were examined
by direct sequencing using reported PCR primers [18]. In the 62 SIG cases,
the entire coding region and splicing boundaries of BRCA1 and of BRCA2
were examined by direct sequencing (BRCA1), or by DHPLC followed by
sequencing (BRCA2), as previously described [19].
MLPA analysis
Altogether 46 BRCAPro-positive probands negative to BRCA1/2 mutation
screening (CIG: 31 cases; SIG: 15 cases) were further tested for BRCA1/2
genomic rearrangements using the MLPA method (Table 1). MLPA was
carried out using the SALSA P002B-BRCA1 and P045-BRCA2 (lot 0905)
MLPA kits (MRC-Holland, Amsterdam, The Netherlands). The P045-
BRCA2 kit, in addition to specific probes for all the BRCA2 exons,
contains also three probes for the low penetrance BC susceptibility gene
CHEK2 [20]. Reaction products were run using an ABI 310 automated
sequencer (Applied Biosystems). As the MLPA signals, particularly for
BRCA1 exons 1a, 1b and 2, may be low when large amounts of DNA
and/or contaminants interfere with denaturation, MLPA results were
always confirmed in three independent experiments, using only 40 ng of
test DNA. Moreover, the MLPA kit includes DNA quantity (DQ) and
DNA denaturation (DD) controls. Obtained MLPA data were analyzed
by GeneScan Analysis software and copied to Excel files (Windows).
Final results were calculated using Coffalyser software (MRC-Holland).
Sample results are displayed as a ratio between reference/experimental
samples. After Coffalyzer analysis, dosage alterations were considered
significant if sample values of peaks area deviated >30% from the values
of at least two normal controls (healthy individuals with no history of
familiar cancer). Two samples with single exon deletion in BRCA1
provided from RESNOVA S.r.l. (Rome, Italy) were included in the
analysis as positive controls.
results
mutation screening
Conventional mutational analyses of the BRCA1/2 genes and,
in one case, of p53 identified 22 pathogenetic germline
mutations, 12 in BRCA1, nine in BRCA2 and one in p53, in
22/177 (12.4%) CIG and SIG probands (Table 2). The p53
mutation [880G>T (E294X), Table 2] was detected in
CIG-110 (CP 90.5%), whose pedigree, with an osteosarcoma-
affected 15-year-old son, satisfied the Li–Fraumeni syndrome
criteria [21].
MLPA analysis
MLPA analysis was carried out in the 46 CIG and SIG
probands with CP >0.1 which resulted BRCA1/2 mutation
negative by conventional analyses. MLPA allowed the
detection of germline BRCA1 rearrangements in three
patients (CIG-70, CIG-75 and CIG-111) with BRCA1 CPs of
99.2%, 85.2% and 70.8%, respectively. In the first two cases
the rearrangements consisted of a deletion involving exons 1a,
1b and 2, while the third case showed a deletion of exon 24.
For CIG-70 it was possible to investigate the segregation of the
BRCA1 deletion with disease in the family (Figures 1 and 2).
Direct sequencing of the ligation sites of the MLPA probes
for BRCA1 exons 1a, 1b and 2 excluded the presence of
mutations/polymorphisms that could have interfered with
probe hybridization. Attempts to identify deletion break
points by long range PCR were unsuccessful due to the
complex structure of the BRCA1 promoter region [22, 23].
The rearrangements were confirmed by Coffalyser software
analysis (Figure 3). In some cases, deletions of BRCA1 exon
24 produce only 25% reductions in the signal of the specific
probe. In our patient, Coffalyzer analysis carried out based
on three different experiments revealed ratios ranging from
0.85 to 0.59. Although a ratio >0.7 should indicate normal
peak size, in CIG-111 all carried out analyses showed
a reduction in exon 24 peak size of at least 25% and
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were interpreted as indicative of a deletion. The search for
break points using long-range PCR primers is in progress
[24].
MLPA analysis for BRCA2 did not show any deletion.
However, a male proband (CIG-84) showed the specific peak
of the CHEK2 1100delC pathogenetic mutation, identified by
the 1772-L1336 probe comprised in the MRC-Holland P045-
BRCA2 MLPA kit.
mutation detection rate
Taken together, conventional mutational screening and MLPA
analysis identified 26 carriers of deleterious germline mutations
Table 1. Characteristics of the 46 probands with CP > 0.1 selected for MLPA analysis
Probands Sex/age Cancer Age at
diagnosis
CP
BRCA1
CP
BRCA2
Total
CP
CIG-2 F/54 bilBC 54 0.118 0.173 0.292
CIG-3 F/22 BC 22 0.256 0.038 0.295
CIG-10 F/41 BC 40 0.028 0.896 0.923
CIG-15 F/35 BC 35 0.300 0.030 0.330
CIG-25 F/45 bilBC 44 0.237 0.028 0.266
CIG-33 F/38 BC 38 0.175 0.092 0.268
CIG-38 F/41 BC 38 0.181 0.013 0.195
CIG-42 F/30 BC 29 0.150 0.024 0.175
CIG-46 F/60 OC 60 0.110 0.016 0.127
CIG-55 F/35 cu / 0.381 0.040 0.422
CIG-60 F/30 cu / 0.222 0.098 0.320
CIG-66 F/26 cu / 0.158 0.014 0.172
CIG-69 F/45 BC 42 0.711 0.163 0.874
CIG-70 F/66 bilBC/OC 33–48 0.992 0.007 1.000
CIG-71 F/37 BC 37 0.493 0.065 0.559
CIG-75 F/33 BC 33 0.852 0.025 0.877
CIG-77 F/47 BC 47 0.593 0.060 0.654
CIG-80 F/52 bilBC 52 0.425 0.089 0.515
CIG-81 F/39 BC 39 0.107 0.002 0.117
CIG-84 M/33 BC 33 0.131 0.140 0.272
CIG-89 F/58 OC 57 0.237 0.240 0.527
CIG-91 F/29 cu / 0.390 0.038 0.431
CIG-93 F/45 BC 44 0.128 0.191 0.32
CIG-94 M/37 BC 31 0.195 0.228 0.424
CIG-95 F/49 BC 49 0.440 0.230 0.67
CIG-96 F/50 bilBC 49 0.122 0.030 0.153
CIG-99 F/63 BC 46 0.464 0.070 0.535
CIG-108 F/50 bilBC 47 0.396 0.31 0.708
CIG-111 F/46 bilBC 37–44 0.708 0.109 0.817
CIG-112 F/50 BC 49 0.094 0.208 0.303
CIG-113 F/39 BC 38 0.827 0.025 0.853
SIG-25BC F/56 BC 50 0.106 0.047 0.153
SIG-37BC F/57 bilBC 49–54 0.104 0.035 0.139
SIG-38BC F/70 cu 66–70 0.036 0.127 0.162
SIG-41BC F/36 BC 36 0.121 0.011 0.132
SIG-55BC F/36 BC 31 0.086 0.027 0.113
SIG-64BC F/35 BC 35 0.0271 0.027 0.298
SIG-71BC F/33 BC 30 0.373 0.032 0.405
SIG-93BC M/70 BC 57 0.044 0.129 0.173
SIG-107BC F/77 bilBC 50–60 0.076 0.040 0.117
SIG-134BC F/56 BC/OC 50–54 0.319 0.133 0.452
SIG-149BC F/54 bilBC 52–52 0.104 0.035 0.139
SIG-62SI F/50 BC 48 0.086 0.027 0.112
SIG-71SI F/40 BC 40 0.216 0.027 0.243
SIG-73SI F/35 BC 34 0.395 0.080 0.475
SIG-77SI F/78 bilBC/OC 42–77/77 0.052 0.136 0.188
CP, carrier probability; MLPA, multiplex ligation-dependent probe amplification; CIG, Central Italian Group; bilBC: bilateral breast cancer; BC: breast cancer;
OC: ovarian cancer; cu: cancer unaffected; SIG, Southern Italian Group; /, in ‘‘age at diagnosis’’ indicates the absence of pathology, as shown in ‘‘cancer’’.
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in 177 investigated probands (14.6%). In detail, we detected 12
BRCA1 point mutations, nine BRCA2 point mutations, three
BRCA1 deletions, one p53 mutation and one CHEK2 mutation.
When considering only patients with CP >10% (BRCAPro
positive), we detected 25 mutations in 67 probands (37.3%).
The only case with CP <10% (BRCAPro-negative) in which
a pathogenetic mutation (in BRCA2) was detected was
a prostate cancer-affected male with BC family history. In this
case, the BRCAPro software most likely failed to correctly
estimate CP.
When considering patients with CPs >50%, we detected
mutations in 11/21 probands (52.3%). The 11 mutations
detected in this very high-risk group included all three BRCA1
deletions, five BRCA1 point mutations, two BRCA2 point
mutations and one p53 mutation. In the group of patients with
CP <50%, we detected 14 mutations in 46 patients (30.4%).
The detected mutations included seven BRCA1 point
mutations, six BRCA2 point mutations and the 1100delC
CHEK2 mutation.
discussion
Despite the high sensitivity of the techniques employed for
BRCA1/2 mutation screening in a large number of patients, no
deleterious point mutations within the BRCA1/2 genes are
detected [1, 4]. In recent years, it has been demonstrated that at
least a portion of the cases negative for BRCA1/2 point
mutations carry genomic rearrangements of BRCA1 or BRCA2,
not detectable by conventional mutation screening, or
mutations in other BC susceptibility genes [4]. Several reports
demonstrated the usefulness of MLPA in the detection of
BRCA1/2 rearrangements [6–13]. However, criteria for the
identification of cases to be submitted to MLPA analysis are
undefined.
Table 2. Characteristics of the 22 probands with mutations in BRCA1/2 or p53 identified by conventional methods
Proband Sex/age Cancer Age at
diagnosis
CP
total
BRCA1 BRCA2 p53
CIG-1 F/55 bilBC 46–54 0.16 c.2596 C>T (R866C)a c.2612C>T
(P871L)a
– NA
CIG-17 F/40 BC 39 0.74 c.4053insT (1351fsX1355)a – NA
CIG-28 F/33 BC 33 0.95 – c.6468_6469delTC (2156fsX2174)a NA
CIG-43 F/54 BC 46 0.44 – c.8961_8964del4 (2987fsX2999)a NA
CIG-49 F/39 OC 39 0.74 c.1380insA (461fsX479)a – NA
CIG-51 F/34 OC 34 0.33 c.3477_3480del4 (1159fsX1208)a – NA
CIG-52 M/51 PC 51 0 – c.5217_5220del4 (1739fsX1739)a NA
CIG-62 M/41 cu / 0.43 c.5277 + 60dup12a – NA
CIG-90 F/30 cu / 0.18 c.5035_5039del5a (1679fsX1680) – NA
CIG-92 F/52 OC/BC 49–52 0.76 c.4117G>T (E1373X)a – NA
CIG-102 F/35 BC 35 0.98 – c.8487 + 1G>A NA
CIG-110 F/43 bilBC 33–41 0.93 – – 880G>T (E294X)
SIG-51BC M/64 BC 60 0.19 c.4327C>Ta NA
SIG-68BC F/70 BC/OC 59–60 0.16 c.6079_6082del4 (1951fsX1961) NA
SIG-79BC F/34 BC 33 0.18 c.6352C>T NA
SIG-85BC F/42 BC 40 0.21 c.7070-19delAT NA
SIG-108BC F/50 bilBC/OC 33–43/50 1.0 c.797_798delTTa NA
SIG-128BC F/58 BC 54 0.39 c.9254_9258de5 (3009fsX3016) NA
SIG-133BC F/43 BC 37 0.16 c.797_798delTTa NA
SIG-146BC F/42 BC 36 0.13 c.303T>Ga NA
SIG-65SI F/42 OC 39 0.92 c.514delCa NA
SIG-82SI F/39 BC 38 0.17 c.6310_6314del5 (2028fsX2046) NA
aPreviously reported [16, 19].
CP, carrier probability; CIG, Central Italian Group; bilBC, bilateral breast cancer; NA, not analyzed; BC, breast cancer; OC, ovarian cancer; PC, prostate
cancer; cu, cancer unaffected; SIG, Southern Italian Group.
Figure 1. Pedigree of proband CIG-70, a 72 years-old woman found to be
carrier of a BRCA1 exons 1–2 deletion identified by MLPA. CIG-70 had
bilateral breast cancer (at ages 33 and 48 years) and ovarian cancer (at age
48). Of the two daughters, the one diagnosed with ovarian cancer at age 43
(CIG-70#1) inherited the mutation, the other one (CIG-70#2), cancer
unaffected at age 43, resulted negative (Br: breast cancer; Ov: ovarian
cancer; Lun: lung cancer).
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In this study, we carried out MLPA analysis of 67 BRCAPro-
positive probands with personal and/or familial BC/OC history
that resulted negative after conventional BRCA1/2 mutation
screening. MLPA allowed to detect genomic BRCA1
rearrangements in 3/21 patients with BRCAPro values >50%
(14.2%). The BRCA1 CP values in the three carriers of BRCA1
rearrangements were very high: 99.2%, 85.2% and 70.8%. In
contrast, no BRCA1/2 alterations were evidenced by MLPA
in 46 BRCAPro-positive probands with CP <50%. This
demonstrates that BRCAPro CP values can importantly
contribute to the identification of probands to be submitted
to MLPA analysis for the detection of rearrangements
within BRCA1.
The BRCA1 deletions detected by MLPA involved in two
cases exons 1 and 2 and in the third case exon 24. We could
not define the break points of these deletion(s).
Rearrangements involving BRCA1 exons 1 and 2 were
previously reported in BC/OC patients of different
geographic origin [6, 8, 22, 23]. In one of our two cases, the
exons 1–2 deletion cosegregated with disease in the family and
we assume a pathogenic role. A BRCA1 exon 24 genomic
rearrangements has been reported in a BC–OC patient from
Greece, geographically close to Italy [24]. Mutations in the
BRCA1 COOH-terminal region may interfere with
important protein functions as well as with messenger RNA
stability and are known to be pathogenic [24–26].
MLPA analysis of BRCA2 did not evidence any deletion,
which is in agreement with literature data reporting a lower
frequency of BRCA2 rearrangements as compared to BRCA1
[27, 4]. This could also be due to the presence of BRCAPro
CP values lower for BRCA2 than for BRCA1. Anyway, in one
male patient with BRCA2 CP 14%, MLPA analysis showed
the presence of the 1100delC CHEK2 mutation. This mutation
is considered to produce a two-fold increase in the risk of
BC in carriers [19]. Thus, despite the low detection rate of
BRCA2 deletions, the use of the MLPA BRCA2 kit can be
considered useful for detecting also the CHEK2 1100delC
mutation.
Figure 2. Multiplex ligation-dependent probe amplification electropherograms from proband CIG-70, her two daughters, CIG-70#1 and CIG-70#2 and
a healthy control (top). Arrows point to the deletion of exons 1–2 of BRCA1 in CIG-70 and in CIG-70#1. The DNA quantity- and DNA denaturation-
control fragments indicate a good amount of DNA and complete denaturation of all samples.
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In conclusion, selection of probands using the BRCAPro
software confirmed to be a powerful tool for the identification
of carriers of both point mutations and deletions in the
BRCA1/2 genes, and of mutations in two other genes related to
cancer susceptibility, p53 and CHECK2.
Selection of patients based on CPs obtained by BRCAPro
allowed to obtain mutation detection rates of 37.3% for CPs
between 10% and 50% and of 52.3% for CPs >50%. On the
other hand, the mutation detection rate in the entire series,
independently from CP-based selection, was significantly lower
(14.6%). Of particular interest is the ability of BRCAPro to
indicate patients who should be submitted to MLPA analysis.
In fact, BRCA1 deletions were detected only in patients showing
upper CP values. Previous studies indicated that the BRCAPro
software overestimates the carrier frequency in cases with CP
>70% [15, 28]. Our results confirm this assumption only for
BRCA1/2 point mutations, which did not show higher
frequency in patients with CP >50% as compared to those
with CP between 10% and 50%. However, a completely
different trend was observed for BRCA1 deletions, which were
detected exclusively in patients with CP >50%. This indicates
that the overestimation of the carrier frequency in patients with
CP >70% may reflect lack of detection of genomic
rearrangements.
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